Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR 31.80
-0.65 (-2.00%)
At close: Jul 27, 2026
BOM:500009 Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 2,025 | 2,025 | 1,973 | 1,743 | 1,710 | 1,976 |
Revenue Growth | 2.64% | 2.64% | 13.20% | 1.92% | -13.46% | 19.66% |
Gross Profit Gross Profit Growth | 811.38 | 811.38 | 789.95 | 717.64 | 666.96 | 812.67 |
Operating Income Operating Income Growth | 189.78 | 189.78 | 126.3 | 81.57 | 101.97 | 258.88 |
Net Income Net Income Growth | 178.04 | 178.04 | 49.31 | 56.81 | 114.47 | 472.19 |
Earnings Per Share EPS Growth | 2.32 | 2.32 | 0.64 | 0.74 | 1.49 | 6.16 |
EPS Growth | 262.50% | 262.50% | -13.51% | -50.34% | -75.81% | 60.83% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceuticals Pharmaceuticals Growth | 1,105 | 1,105 | 1,084 | 926.93 | 1,014 | 1,365 |
Electronics Electronics Growth | 917.76 | 917.76 | 877.51 | 808.77 | 689.12 | 602.27 |
Inter Segment Inter Segment Growth | -0.11 | -0.11 | - | - | - | - |
Total Total Growth | 2,023 | 2,023 | 1,962 | 1,736 | 1,703 | 1,967 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 166.26 | 166.26 | 87.21 | 267.2 | 252.05 | 254.66 |
Total Debt Total Debt Growth | 565.29 | 565.29 | 508.87 | 461.13 | 451.96 | 267.5 |
Net Cash (Debt) Net Cash Growth | -399.04 | -399.04 | -421.66 | -193.93 | -199.91 | -12.84 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -5.21 | -5.21 | -5.50 | -2.53 | -2.61 | -0.17 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 134 | 134 | -176.23 | 88.87 | 57.25 | 114.72 |
Capital Expenditures CapEx Growth | -42.43 | -42.43 | -27.18 | -29.11 | -206.68 | -157.11 |
Free Cash Flow Free Cash Flow Growth | 91.57 | 91.57 | -203.41 | 59.76 | -149.44 | -42.39 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 40.06% | 40.06% | 40.03% | 41.17% | 38.99% | 41.12% |
Operating Margin | 9.37% | 9.37% | 6.40% | 4.68% | 5.96% | 13.10% |
Pretax Margin | 9.14% | 9.14% | 2.45% | 3.82% | 8.87% | 27.42% |
Profit Margin | 8.79% | 8.79% | 2.50% | 3.26% | 6.69% | 23.89% |
FCF Margin | 4.52% | 4.52% | -10.31% | 3.43% | -8.74% | -2.15% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 13.71 | 10.45 | 54.47 | 61.35 | 13.73 | 5.66 |
P/FCF Ratio | 26.61 | 20.31 | - | 58.32 | - | - |
PS Ratio | 1.20 | 0.92 | 1.36 | 2.00 | 0.92 | 1.35 |